Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77644 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HPGDSMN1; SMN2KDM4EPOLB | |
| SCHEMBL1614216 | 0.78 | ALDH1A1 (0.35) | ALDH1A1HPGDSMN1; SMN2KDM4EPOLB | |
| SCHEMBL19309250 | 0.77 | ALDH1A1 (0.36) | ALDH1A1HPGDSMN1; SMN2KDM4EPOLB | |
| SCHEMBL25308644 | 0.77 | KDM4E (0.33) | SMN1; SMN2KDM4EGAAMAPTRAB9A | |
| SCHEMBL11351815 | 0.77 | ALDH1A1 (0.36) | ALDH1A1HPGDSMN1; SMN2KDM4EPOLB | |
| SCHEMBL10223181 | 0.76 | CCR4 (0.33) | ALDH1A1HPGDSMN1; SMN2KDM4EPOLB | |
| SCHEMBL3605034 | 0.76 | SMN1; SMN2 (0.46) | ALDH1A1HPGDSMN1; SMN2KDM4EPOLB | |
| SCHEMBL8802935 | 0.76 | CCR4 (0.30) | CCR4 | |
| SCHEMBL5537262 | 0.75 | SMN1; SMN2 (0.46) | ALDH1A1HPGDSMN1; SMN2KDM4EPOLB | |
| SCHEMBL343104 | 0.74 | LMNA (0.41) | ALDH1A1HPGDSMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445749-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | ALDH1A1 3887/4885HPGD 2844/4885SMN1; SMN2 4859/4885 |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | ALDH1A1 2729/4885HPGD 786/4885SMN1; SMN2 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.